CAP TODAY/AstraZeneca Webinar: Molecular Testing for Alterations in DNA Damage Repair Pathway Genes in Ovarian and Prostate Cancer: Why, Who, and How to Test

Thank you

This live web event has ended. Thank you for attending.

Description

Molecular Testing for Alterations
in DNA Damage Repair Pathway Genes
in Ovarian and Prostate Cancer:
Why, Who, and How to Test

Why should you register now for this webinar?
Hear national thought leaders discuss the following topics:

Prevalence of HRD in patients with ovarian cancer and the rationale for HRD testing
Prevalence of HRRm in patients with prostate cancer and the rationale for HRRm testing
Current guideline recommendations for molecular testing in ovarian and prostate cancer, and sample type options and considerations

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenters: Stephen Freedland, MD, and John Longshore, PhD, FACMG
You will have the opportunity to ask questions of our distinguished presenters.

CAP TODAY does not endorse any of the products or services named within.
©2020 AstraZeneca. All rights reserved.
US-45791 9/20

Contributors

Bob McGonnagle

Publisher, CAP TODAY
Stephen Freedland, MD

Staff Physician, Durham VA Medical Center
Director, Center for Integrated Research in
Cancer & Lifestyle
Associate Director, Education and Training,
Cedars-Sinai Cancer; Professor of Surgery (Urology), Cedars-Sinai Medical Center
John Longshore, PhD, FACMG

John Longshore, PhD, FACMG
Director, Molecular Pathology
Carolinas Pathology Group, Atrium Health